CARM Financial Statements | Balance Sheet, Income & Cash Flow Analysis
The financial statements for CARM (CARM) provide a snapshot of revenue trends, balance-sheet strength, and cash flow quality. Reviewing these together helps investors evaluate earnings durability, capital structure, and whether operating cash flow supports long-term business growth.
See stock fair value and complete historical financials—premium unlocks deeper tables and metrics.
Financial Statements
Related peers
Compare More →| A Agilent Technologies, Inc. | $120.40 +2.47% |
| SLRX Salarius Pharmaceuticals, Inc. | $0.84 +29.23% |
| ASBP Aspire Biopharma Holdings, Inc. | $1.19 +4.39% |
| SPRC SciSparc Ltd. | $3.23 +5.38% |
| INDP Indaptus Therapeutics, Inc. | $2.33 +13.11% |
| JSPR Jasper Therapeutics, Inc. | $0.93 +1.46% |
| Peer | Price | Change | Market Cap | PE | EPS | Div Yield (TTM) | Analyst Rating | Volume |
|---|---|---|---|---|---|---|---|---|
| A Agilent Technologies, Inc. | $120.40 | +2.47% | 34.05 B | 26.58 | 4.53 | 0.84% | Buy | 1.81 |
| SLRX Salarius Pharmaceuticals, Inc. | $0.84 | +29.23% | 4.92 M | -0.03 | -24.24 | 0.00% | Hold | 5.96 |
| ASBP Aspire Biopharma Holdings, Inc. | $1.19 | +4.39% | 4.12 M | -0.07 | -16.38 | 0.00% | — | 117 |
| SPRC SciSparc Ltd. | $3.23 | +5.38% | 186820 | 0.00 | 3156.52 | 0.00% | — | 7 |
| INDP Indaptus Therapeutics, Inc. | $2.33 | +13.11% | 4.08 M | -0.11 | -21.58 | 0.00% | Buy | 250 |
| JSPR Jasper Therapeutics, Inc. | $0.93 | +1.46% | 15.15 M | -0.24 | -3.95 | 0.00% | Buy | 532 |
Frequently Asked Questions
What are CARM's latest financial results?
Review CARM's latest balance sheet, income statement, and cash flow to understand its profitability, revenue trends, and financial health. These metrics are essential for evaluating short-term performance and long-term stability.
How has CARM's revenue and net income changed over time?
Analyzing historical revenue and net income shows growth trends and business performance. Consistent growth indicates operational strength, while declines may signal challenges that investors should consider.
What is CARM's cash flow situation and liquidity?
Cash flow statements reveal how CARM generates and uses cash. Strong operating cash flow and sufficient liquidity suggest the company can fund operations, pay dividends, and handle debt effectively.
How does CARM's financial performance compare to industry peers?
Comparing key metrics like revenue growth, profit margins, and debt levels with competitors helps investors assess whether CARM is outperforming or lagging within its sector.
Are CARM's financial statements showing sustainable profitability?
By analyzing margins, ROE, ROIC, and cash generation over multiple periods, investors can evaluate whether CARM's profits are repeatable and supported by strong fundamentals.